Alex L E Halme
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex L E Halme has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Kari A. O. Tikkinen
Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
7 shared publications - Negar Pourjamal
Faculty of Medicine, University of Helsinki, Helsinki, Finland
5 shared publications - Gordon Henry Guyatt
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
4 shared publications - Herney Andrés García-Perdomo
UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia
3 shared publications - Marcus Hendrikus Blanker
Department of Primary and Long‐term Care University of Groningen, University Medical Center Groningen Groningen The Netherlands
3 shared publications - Rufus Cartwright
Department of Gynaecology, Chelsea and Westminster NHS Foundation Trust, London, UK
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102563
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
- 17 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102563
Open AccessInternational Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
- Open Access
- 9 September 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001343
Effectiveness of different de-implementation strategies in primary care: systematic review and meta-analysis
Objective: To evaluate the effectiveness of various de-implementation interventions in primary care, targeting care (treatments or tests) that provides no or limited value for patients (low value care). Design: Systematic review and meta-analysis. Data sources: Medline and Scopus databases, from inception to 10 July 2024. Eligibility criteria for selecting studies: Randomised trials comparing de-implementation interventions with placebo or sham intervention, no intervention, or other de-implementation intervention strategies in primary care. Eligible trials provided information on the use of low value care, total volume of care, appropriate care, and health outcomes. Data extraction and synthesis: Titles, abstracts, and full texts were screened, data were extracted, and risk of bias was assessed independently and in duplicate. Random effects meta-analyses were conducted, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: 13 008 abstracts were screened and 140 were eligible for inclusion in the study. Median follow-up was 287 days (interquartile range 180-365). In 75 (54%) trials the aim was to reduce the use of antibiotics, in 42 (30%) to reduce other drug treatments, in 17 (12%) to reduce imaging, and in 15 (11%) to reduce laboratory testing. The certainty of the evidence was moderate that provider education combined with audit and feedback reduced the use of targeted low value care (odds ratio 0.73, 95% confidence interval (95% CI) 0.63 to 0.84). Provider education (0.86, 95% CI 0.72 to 1.03), audit and feedback (0.82, 0.67 to 1.00), and patient education (0.70, 0.30 to 1.66), and a combination of these strategies (point estimates for odds ratios ranging from 0.57 to 0.64) may reduce the use of targeted low value care (low certainty of evidence for all). Conclusions: The results suggested with moderate certainty of evidence that provider education combined with audit and feedback reduced the use of targeted low value care. Individual strategies may slightly reduce the use of targeted low value care, but achieving a meaningful impact on low value care may require the use of multiple strategies. The results may be useful for patients, clinicians, policy makers, and guideline developers when deciding on future de-implementation strategies and research priorities. Systematic review registration: PROSPERO CRD42023411768.
- 9 September 2025
- Published by BMJ in BMJ Medicine
- Vol. 4 (1) , e001343
Open AccessEffectiveness of different de-implementation strategies in primary care: systematic review and meta-analysis
Objective: To evaluate the effectiveness of various de-implementation interventions in primary care, targeting care (treatments or tests) that provides no or limited value for patients (low value care). Design: Systematic review and meta-analysis. Data sources: Medline and Scopus databases, from inception to 10 July 2024. Eligibility criteria for selecting studies: Randomised trials comparing de-implementation interventions with placebo or sham intervention, no intervention, or other de-implementation intervention strategies in primary care. Eligible trials provided information on the use of low value care, total volume of care, appropriate care, and health outcomes. Data extraction and synthesis: Titles, abstracts, and full texts were screened, data were extracted, and risk of bias was assessed independently and in duplicate. Random effects meta-analyses were conducted, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: 13 008 abstracts were screened and 140 were eligible for inclusion in the study. Median follow-up was 287 days (interquartile range 180-365). In 75 (54%) trials the aim was to reduce the use of antibiotics, in 42 (30%) to reduce other drug treatments, in 17 (12%) to reduce imaging, and in 15 (11%) to reduce laboratory testing. The certainty of the evidence was moderate that provider education combined with audit and feedback reduced the use of targeted low value care (odds ratio 0.73, 95% confidence interval (95% CI) 0.63 to 0.84). Provider education (0.86, 95% CI 0.72 to 1.03), audit and feedback (0.82, 0.67 to 1.00), and patient education (0.70, 0.30 to 1.66), and a combination of these strategies (point estimates for odds ratios ranging from 0.57 to 0.64) may reduce the use of targeted low value care (low certainty of evidence for all). Conclusions: The results suggested with moderate certainty of evidence that provider education combined with audit and feedback reduced the use of targeted low value care. Individual strategies may slightly reduce the use of targeted low value care, but achieving a meaningful impact on low value care may require the use of multiple strategies. The results may be useful for patients, clinicians, policy makers, and guideline developers when deciding on future de-implementation strategies and research priorities. Systematic review registration: PROSPERO CRD42023411768.
- Open Access
- 28 May 2025
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (5)
Evidence categories in systematic assessment of cancer overdiagnosis
The phenomenon of cancer overdiagnosis, the diagnosis of a malignant tumour that, without detection, would never lead to adverse health effects, has been reported for several cancer types in different populations. There has been an increase in studies focused on overdiagnosis, creating an opportunity to synthesise evidence on specific cancer types. However, studies that systematically assess evidence across different research domains remain scarce, with most of them relying on data from studies that already mentioned overdiagnosis as a potential concern. In this review, we consider several evidence categories that are used to systematically assess the presence and magnitude of overdiagnosis, including (1) data from cancer surveillance, (2) studies exploring the ‘true’ prevalence of cancer in the population, (3) studies that explore the use of diagnostics and its effect on incidence and mortality and (4) studies that explore changes and progress in cancer management and its effect on cancer mortality. This article highlights the strengths and weaknesses of different evidence categories, provides examples of studies on different cancer types and discusses how these categories can help synthesise evidence on cancer overdiagnosis.
- 28 May 2025
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 30 (5)
Open AccessEvidence categories in systematic assessment of cancer overdiagnosis
The phenomenon of cancer overdiagnosis, the diagnosis of a malignant tumour that, without detection, would never lead to adverse health effects, has been reported for several cancer types in different populations. There has been an increase in studies focused on overdiagnosis, creating an opportunity to synthesise evidence on specific cancer types. However, studies that systematically assess evidence across different research domains remain scarce, with most of them relying on data from studies that already mentioned overdiagnosis as a potential concern. In this review, we consider several evidence categories that are used to systematically assess the presence and magnitude of overdiagnosis, including (1) data from cancer surveillance, (2) studies exploring the ‘true’ prevalence of cancer in the population, (3) studies that explore the use of diagnostics and its effect on incidence and mortality and (4) studies that explore changes and progress in cancer management and its effect on cancer mortality. This article highlights the strengths and weaknesses of different evidence categories, provides examples of studies on different cancer types and discusses how these categories can help synthesise evidence on cancer overdiagnosis.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1505
Short- and long-term effects of imatinib in patients hospitalised for COVID-19: A randomised trial
Background: Earlier evidence has suggested that imatinib may improve 30-day survival in hospitalised COVID-19 patients. Objective: To study the short- and long-term effects of imatinib in hospitalised COVID-19 patients. Methods: We conducted a randomised trial in 15 Finnish hospitals. Participants were randomised between locally available options to receive standard or care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of all randomised trials studying imatinib for 30-day mortality in hospitalised COVID-19 patients. Results: Between August 2021 and March 2023, we randomised 156 patients (103 in 2021, 51 in 2022 and 2 in 2023; 73 in SoC, 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year and among those randomized to SoC 4.1% and 8.3% (adjusted HR 1.09, 95% CI 0.23–5.07). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in SoC (RR 0.91, 0.78-1.06). We found no convincing difference between groups in quality of life or symptoms. Fatigue (24%), sleep issues (19%), and memory problems (17%) frequently bothered patients among 21 potential long COVID symptoms. In the meta-analysis of 4 randomised trials (732 patients), imatinib was associated with a mortality risk ratio of 0.73 (0.32–1.63; low certainty evidence). Conclusions: The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalised COVID-19 patients.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1505
Short- and long-term effects of imatinib in patients hospitalised for COVID-19: A randomised trial
Background: Earlier evidence has suggested that imatinib may improve 30-day survival in hospitalised COVID-19 patients. Objective: To study the short- and long-term effects of imatinib in hospitalised COVID-19 patients. Methods: We conducted a randomised trial in 15 Finnish hospitals. Participants were randomised between locally available options to receive standard or care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of all randomised trials studying imatinib for 30-day mortality in hospitalised COVID-19 patients. Results: Between August 2021 and March 2023, we randomised 156 patients (103 in 2021, 51 in 2022 and 2 in 2023; 73 in SoC, 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year and among those randomized to SoC 4.1% and 8.3% (adjusted HR 1.09, 95% CI 0.23–5.07). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in SoC (RR 0.91, 0.78-1.06). We found no convincing difference between groups in quality of life or symptoms. Fatigue (24%), sleep issues (19%), and memory problems (17%) frequently bothered patients among 21 potential long COVID symptoms. In the meta-analysis of 4 randomised trials (732 patients), imatinib was associated with a mortality risk ratio of 0.73 (0.32–1.63; low certainty evidence). Conclusions: The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalised COVID-19 patients.
- Open Access
- 3 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (3) , 106217
Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial
- 3 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (3) , 106217
Open AccessShort- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial
- Top Cited PapersOpen Access
- 1 April 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (4) , e244581
Timing of Major Postoperative Bleeding Among Patients Undergoing Surgery
More than 300 million patients undergo surgery annually worldwide.1 Bleeding is among the most common surgical complications and is associated with blood transfusion, reintervention, organ injury, and death, as well as increased costs.2-4 Surgical patients often receive prophylactic or therapeutic anticoagulant and antiplatelet medications. Postoperative bleeding risk, which dissipates after surgery, is relevant for decisions about when to use these agents.
- 1 April 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (4) , e244581
Top Cited PapersOpen AccessTiming of Major Postoperative Bleeding Among Patients Undergoing Surgery
More than 300 million patients undergo surgery annually worldwide.1 Bleeding is among the most common surgical complications and is associated with blood transfusion, reintervention, organ injury, and death, as well as increased costs.2-4 Surgical patients often receive prophylactic or therapeutic anticoagulant and antiplatelet medications. Postoperative bleeding risk, which dissipates after surgery, is relevant for decisions about when to use these agents.
- 7 November 2023
- Published by Elsevier in European Urology Focus
- Vol. 9 (5) , 693-694
Fixed-effect Versus Random-effects Models for Meta-analyses: Random-effects Models
- 7 November 2023
- Published by Elsevier in European Urology Focus
- Vol. 9 (5) , 693-694
Fixed-effect Versus Random-effects Models for Meta-analyses: Random-effects Models
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 279 (2) , 213-225
Systematic Reviews and Meta-analyses of the Procedure-specific Risks of Thrombosis and Bleeding in General Abdominal, Colorectal, Upper Gastrointestinal, and Hepatopancreatobiliary Surgery
Objective: To provide procedure-specific estimates of symptomatic venous thromboembolism (VTE) and major bleeding after abdominal surgery. Background: The use of pharmacological thromboprophylaxis represents a trade-off that depends on VTE and bleeding risks that vary between procedures; their magnitude remains uncertain. Methods: We identified observational studies reporting procedure-specific risks of symptomatic VTE or major bleeding after abdominal surgery, adjusted the reported estimates for thromboprophylaxis and length of follow-up, and estimated cumulative incidence at 4 weeks postsurgery, stratified by VTE risk groups, and rated evidence certainty. Results: After eligibility screening, 285 studies (8,048,635 patients) reporting on 40 general abdominal, 36 colorectal, 15 upper gastrointestinal, and 24 hepatopancreatobiliary surgery procedures proved eligible. Evidence certainty proved generally moderate or low for VTE and low or very low for bleeding requiring reintervention. The risk of VTE varied substantially among procedures: in general abdominal surgery from a median of <0.1% in laparoscopic cholecystectomy to a median of 3.7% in open small bowel resection, in colorectal from 0.3% in minimally invasive sigmoid colectomy to 10.0% in emergency open total proctocolectomy, and in upper gastrointestinal/hepatopancreatobiliary from 0.2% in laparoscopic sleeve gastrectomy to 6.8% in open distal pancreatectomy for cancer. Conclusions: VTE thromboprophylaxis provides net benefit through VTE reduction with a small increase in bleeding in some procedures (eg, open colectomy and open pancreaticoduodenectomy), whereas the opposite is true in others (eg, laparoscopic cholecystectomy and elective groin hernia repairs). In many procedures, thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding VTE and bleeding.
- 8 August 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 279 (2) , 213-225
Open AccessSystematic Reviews and Meta-analyses of the Procedure-specific Risks of Thrombosis and Bleeding in General Abdominal, Colorectal, Upper Gastrointestinal, and Hepatopancreatobiliary Surgery
Objective: To provide procedure-specific estimates of symptomatic venous thromboembolism (VTE) and major bleeding after abdominal surgery. Background: The use of pharmacological thromboprophylaxis represents a trade-off that depends on VTE and bleeding risks that vary between procedures; their magnitude remains uncertain. Methods: We identified observational studies reporting procedure-specific risks of symptomatic VTE or major bleeding after abdominal surgery, adjusted the reported estimates for thromboprophylaxis and length of follow-up, and estimated cumulative incidence at 4 weeks postsurgery, stratified by VTE risk groups, and rated evidence certainty. Results: After eligibility screening, 285 studies (8,048,635 patients) reporting on 40 general abdominal, 36 colorectal, 15 upper gastrointestinal, and 24 hepatopancreatobiliary surgery procedures proved eligible. Evidence certainty proved generally moderate or low for VTE and low or very low for bleeding requiring reintervention. The risk of VTE varied substantially among procedures: in general abdominal surgery from a median of <0.1% in laparoscopic cholecystectomy to a median of 3.7% in open small bowel resection, in colorectal from 0.3% in minimally invasive sigmoid colectomy to 10.0% in emergency open total proctocolectomy, and in upper gastrointestinal/hepatopancreatobiliary from 0.2% in laparoscopic sleeve gastrectomy to 6.8% in open distal pancreatectomy for cancer. Conclusions: VTE thromboprophylaxis provides net benefit through VTE reduction with a small increase in bleeding in some procedures (eg, open colectomy and open pancreaticoduodenectomy), whereas the opposite is true in others (eg, laparoscopic cholecystectomy and elective groin hernia repairs). In many procedures, thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding VTE and bleeding.
- Open Access
- 13 March 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (5) , 553-561
Timing of symptomatic venous thromboembolism after surgery: meta-analysis
Background: The timing at which venous thromboembolism (VTE) occurs after major surgery has major implications for the optimal duration of thromboprophylaxis. The aim of this study was to perform a systematic review and meta-analysis of the timing of postoperative VTE up to 4 weeks after surgery. Methods: A systematic search of MEDLINE, Scopus, and CINAHL databases was performed between 1 January 2009 and 1 April 2022. Prospective studies that recruited patients who underwent a surgical procedure and reported at least 20 symptomatic, postoperative VTE events by time were included. Two reviewers independently selected studies according to the eligibility criteria, extracted data, and evaluated risk of bias. Data were analysed with a Poisson regression model, and the GRADE approach was used to rate the certainty of evidence. Results: Some 6258 studies were evaluated, of which 22 (11 general, 5 urological, 4 mixed, and 2 orthopaedic postoperative surgical populations; total 1 864 875 patients and 24 927 VTE events) were eligible. Pooled evidence of moderate certainty showed that 47.1 per cent of the VTE events occurred during the first, 26.9 per cent during the second, 15.8 per cent during the third, and 10.1 per cent during the fourth week after surgery. The timing of VTE was consistent between individual studies. Conclusion: Although nearly half of symptomatic VTE events in first 4 weeks occur during the first postoperative week, a substantial number of events occur several weeks after surgery. These data will inform clinicians and guideline developers about the duration of postoperative thromboprophylaxis.
- 13 March 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (5) , 553-561
Open AccessTiming of symptomatic venous thromboembolism after surgery: meta-analysis
Background: The timing at which venous thromboembolism (VTE) occurs after major surgery has major implications for the optimal duration of thromboprophylaxis. The aim of this study was to perform a systematic review and meta-analysis of the timing of postoperative VTE up to 4 weeks after surgery. Methods: A systematic search of MEDLINE, Scopus, and CINAHL databases was performed between 1 January 2009 and 1 April 2022. Prospective studies that recruited patients who underwent a surgical procedure and reported at least 20 symptomatic, postoperative VTE events by time were included. Two reviewers independently selected studies according to the eligibility criteria, extracted data, and evaluated risk of bias. Data were analysed with a Poisson regression model, and the GRADE approach was used to rate the certainty of evidence. Results: Some 6258 studies were evaluated, of which 22 (11 general, 5 urological, 4 mixed, and 2 orthopaedic postoperative surgical populations; total 1 864 875 patients and 24 927 VTE events) were eligible. Pooled evidence of moderate certainty showed that 47.1 per cent of the VTE events occurred during the first, 26.9 per cent during the second, 15.8 per cent during the third, and 10.1 per cent during the fourth week after surgery. The timing of VTE was consistent between individual studies. Conclusion: Although nearly half of symptomatic VTE events in first 4 weeks occur during the first postoperative week, a substantial number of events occur several weeks after surgery. These data will inform clinicians and guideline developers about the duration of postoperative thromboprophylaxis.
- Open Access
- 7 October 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (5)
Global practice variation in pharmacologicthromboprophylaxis for general and gynaecologicalsurgery: systematic review
Dear Editor
- 7 October 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (5)
Open AccessGlobal practice variation in pharmacologicthromboprophylaxis for general and gynaecologicalsurgery: systematic review
Dear Editor